{"id":"https://openalex.org/W4413098237","doi":"https://doi.org/10.2337/figshare.29469482","title":"Effects of Semaglutide With or Without Concomitant Mineralocorticoid Receptor Antagonist Use in Participants With Type 2 Diabetes and Chronic Kidney Disease: A FLOW Trial Pre-Specified Secondary Analysis","display_name":"Effects of Semaglutide With or Without Concomitant Mineralocorticoid Receptor Antagonist Use in Participants With Type 2 Diabetes and Chronic Kidney Disease: A FLOW Trial Pre-Specified Secondary Analysis","publication_year":2025,"publication_date":"2025-07-29","ids":{"openalex":"https://openalex.org/W4413098237","doi":"https://doi.org/10.2337/figshare.29469482"},"language":"en","primary_location":{"id":"doi:10.2337/figshare.29469482","doi":"https://doi.org/10.2337/figshare.29469482","is_oa":true,"landing_page_url":"https://doi.org/10.2337/figshare.29469482","pdf_url":null,"source":null,"license":"cc-by-nc-sa","license_id":"https://openalex.org/licenses/cc-by-nc-sa","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Diabetes Association","raw_type":"posted-content"},"volume":null,"type":"other","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.2337/figshare.29469482","any_repository_has_fulltext":null},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5085592050","display_name":"Peter R Rossing","orcid":"https://orcid.org/0000-0002-1531-4294","observed_orcids":["https://orcid.org/0000-0002-1531-4294","https://orcid.org/0009-0004-5073-0009"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Peter Rossing","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012514694","display_name":"George L. Bakris","orcid":"https://orcid.org/0000-0003-1183-1267","observed_orcids":["https://orcid.org/0000-0003-1183-1267"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"George Bakris","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027520502","display_name":"Vlado Perkovic","orcid":"https://orcid.org/0000-0002-4257-7620","observed_orcids":["https://orcid.org/0000-0002-4257-7620"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Vlado Perkovic","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059098934","display_name":"Richard E. Pratley","orcid":"https://orcid.org/0000-0002-2912-1389","observed_orcids":["https://orcid.org/0000-0002-2912-1389"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Richard Pratley","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046793050","display_name":"Katherine R. Tuttle","orcid":"https://orcid.org/0000-0002-2235-0103","observed_orcids":["https://orcid.org/0000-0002-2235-0103"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Katherine R. Tuttle","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039432822","display_name":"Kenneth W. Mahaffey","orcid":"https://orcid.org/0000-0002-3791-2148","observed_orcids":["https://orcid.org/0000-0002-3791-2148"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kenneth W. Mahaffey","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113682378","display_name":"Thomas Idorn","orcid":"https://orcid.org/0009-0009-4896-5868","observed_orcids":["https://orcid.org/0009-0009-4896-5868"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Thomas Idorn","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113262208","display_name":"Nicolas Belmar","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Nicolas Belmar","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070579413","display_name":"Heidrun Bosch\u2010Traberg","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Heidrun Bosch-Traberg","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5019715513","display_name":"S\u00f8ren Rasmussen","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"S\u00f8ren Rasmussen","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103165011","display_name":"Robert S. Busch","orcid":"https://orcid.org/0000-0002-7172-2815","observed_orcids":["https://orcid.org/0000-0002-7172-2815"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Robert S. Busch","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"Ronald E. Schmieder","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ronald E. Schmieder","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070914221","display_name":"Pieter Gillard","orcid":"https://orcid.org/0000-0001-9111-4561","observed_orcids":["https://orcid.org/0000-0001-9111-4561"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Pieter Gillard","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5043842967","display_name":"Johannes F.E. Mann","orcid":"https://orcid.org/0000-0002-3154-5332","observed_orcids":["https://orcid.org/0000-0002-3154-5332"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Johannes F.E. Mann","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.5605000257492065,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.5605000257492065,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10408","display_name":"Chronic Kidney Disease and Diabetes","score":0.4262999892234802,"subfield":{"id":"https://openalex.org/subfields/2727","display_name":"Nephrology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10198","display_name":"Heart Failure Treatment and Management","score":0.0026000000070780516,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/semaglutide","display_name":"semaglutide","score":0.9990000128746033},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.8629999756813049},{"id":"https://openalex.org/keywords/chronic-kidney-disease","display_name":"chronic kidney disease","score":1.0},{"id":"https://openalex.org/keywords/mineralocorticoid-receptor-antagonists","display_name":"mineralocorticoid receptor antagonists","score":0.9879999756813049},{"id":"https://openalex.org/keywords/spironolactone","display_name":"spironolactone","score":0.9860000014305115},{"id":"https://openalex.org/keywords/finerenone","display_name":"finerenone","score":0.9900000095367432},{"id":"https://openalex.org/keywords/albuminuria","display_name":"albuminuria","score":0.7089999914169312},{"id":"https://openalex.org/keywords/estimated-glomerular-filtration-rate-decline","display_name":"estimated glomerular filtration rate decline","score":0.9229999780654907},{"id":"https://openalex.org/keywords/kidney-failure","display_name":"renal failure","score":0.8840000033378601},{"id":"https://openalex.org/keywords/major-adverse-cardiovascular-events","display_name":"major adverse cardiovascular events","score":0.9879999756813049},{"id":"https://openalex.org/keywords/all-cause-mortality","display_name":"all-cause mortality","score":0.9990000128746033},{"id":"https://openalex.org/keywords/flow-trial","display_name":"FLOW trial","score":0.6690000295639038},{"id":"https://openalex.org/keywords/subgroup-analysis","display_name":"subgroup analysis","score":0.5009999871253967},{"id":"https://openalex.org/keywords/drug-interactions","display_name":"drug interactions","score":0.5849999785423279},{"id":"https://openalex.org/keywords/glp-1-receptor-agonists","display_name":"GLP-1 receptor agonists","score":0.8199999928474426},{"id":"https://openalex.org/keywords/renal-protection","display_name":"renal protection","score":0.6899999976158142}],"concepts":[{"id":"https://openalex.org/C2909862629","wikidata":"https://www.wikidata.org/wiki/Q27261089","display_name":"Semaglutide","level":5,"score":0.9811782836914062},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7736225128173828},{"id":"https://openalex.org/C2778653478","wikidata":"https://www.wikidata.org/wiki/Q1054718","display_name":"Kidney disease","level":2,"score":0.6395043730735779},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6016351580619812},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.5973464250564575},{"id":"https://openalex.org/C207103383","wikidata":"https://www.wikidata.org/wiki/Q3930246","display_name":"Hazard ratio","level":3,"score":0.5057122707366943},{"id":"https://openalex.org/C189135053","wikidata":"https://www.wikidata.org/wiki/Q3454531","display_name":"Mineralocorticoid receptor","level":3,"score":0.4258868992328644},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.41244372725486755},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.3794019818305969},{"id":"https://openalex.org/C126894567","wikidata":"https://www.wikidata.org/wiki/Q105650","display_name":"Urology","level":1,"score":0.36717942357063293},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.35496023297309875},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.15906807780265808},{"id":"https://openalex.org/C2778525890","wikidata":"https://www.wikidata.org/wiki/Q184564","display_name":"Aldosterone","level":2,"score":0.09240156412124634},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.06085413694381714},{"id":"https://openalex.org/C2781308992","wikidata":"https://www.wikidata.org/wiki/Q2526479","display_name":"Liraglutide","level":4,"score":0.060028076171875},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.2337/figshare.29469482","doi":"https://doi.org/10.2337/figshare.29469482","is_oa":true,"landing_page_url":"https://doi.org/10.2337/figshare.29469482","pdf_url":null,"source":null,"license":"cc-by-nc-sa","license_id":"https://openalex.org/licenses/cc-by-nc-sa","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Diabetes Association","raw_type":"posted-content"}],"best_oa_location":{"id":"doi:10.2337/figshare.29469482","doi":"https://doi.org/10.2337/figshare.29469482","is_oa":true,"landing_page_url":"https://doi.org/10.2337/figshare.29469482","pdf_url":null,"source":null,"license":"cc-by-nc-sa","license_id":"https://openalex.org/licenses/cc-by-nc-sa","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Diabetes Association","raw_type":"posted-content"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4403833769","https://openalex.org/W4399940216","https://openalex.org/W7130388323","https://openalex.org/W4398781461","https://openalex.org/W4317213523","https://openalex.org/W4402050123","https://openalex.org/W4416564260","https://openalex.org/W4416880986","https://openalex.org/W7163154939","https://openalex.org/W7166455367"],"abstract_inverted_index":{"Objective:":[0],"In":[1,225],"FLOW,":[2],"semaglutide":[3,36,60,163,188,213,219,234],"reduced":[4,118,184,211],"the":[5,33,119,122,160],"risk":[6,120],"of":[7,35,72,121,162,218,233,246],"major":[8,165,236],"kidney":[9,26,67,82,124,237],"and":[10,14,24,40,52,113,138,151,170,198,229,240],"cardiovascular":[11],"(CV)":[12],"outcomes":[13,42],"all-cause":[15,171,241],"mortality":[16,41,172,242],"in":[17,149,173,195,202],"people":[18],"with":[19,187,212,227],"type":[20],"2":[21],"diabetes":[22],"(T2D)":[23],"chronic":[25],"disease":[27],"(CKD).":[28],"This":[29],"prespecified":[30],"analysis":[31],"assessed":[32],"effects":[34,161],"on":[37,164,235],"kidney,":[38],"CV":[39,167],"by":[43,106,126,189],"baseline":[44,107,186,247],"mineralocorticoid":[45],"receptor":[46],"antagonist":[47],"(MRA)":[48],"use.":[49,249],"Research":[50],"Design":[51],"Methods:":[53],"Participants":[54],"were":[55,104,243],"randomized":[56],"to":[57,74,87],"once-weekly":[58],"subcutaneous":[59],"1.0":[61],"mg":[62],"or":[63,84],"placebo.":[64],"The":[65,215],"primary":[66,123],"outcome":[68,125],"was":[69,92,96,156,183,209,220],"a":[70],"composite":[71],"time":[73],"first":[75],"persistent":[76],"\u226550%":[77],"eGFR":[78,207],"reduction":[79],"from":[80,185],"baseline,":[81],"failure,":[83],"death":[85],"due":[86],"kidney/CV":[88],"causes.":[89],"Baseline":[90],"MRA":[91,108,150,175,196,248],"predominantly":[93],"spironolactone,":[94],"finerenone":[95],"only":[97],"available":[98],"after":[99],"recruitment":[100],"ended.":[101],"Results:":[102],"Effects":[103],"analyzed":[105],"use":[109],"(n=257":[110],"[136/121":[111],"semaglutide/placebo])":[112],"non-use":[114],"(n=3,276":[115],"[1631/1645]).":[116],"Semaglutide":[117],"49%":[127],"(59":[128],"events,":[129,141],"hazard":[130],"ratio":[131],"[HR]":[132],"0.51;":[133],"95%":[134],"CI":[135,192],"0.30,":[136],"0.86)":[137],"21%":[139],"(682":[140],"HR":[142],"0.79;":[143],"0.68,":[144],"0.92;":[145],"P-interaction=0.12)":[146],"versus":[147,204],"placebo":[148,205],"non-MRA":[152],"subgroups,":[153],"respectively.":[154],"There":[155],"no":[157],"heterogeneity,":[158],"favoring":[159],"adverse":[166],"events":[168],"(MACE)":[169],"both":[174],"subgroups":[176],"(P-interaction":[177],">0.7).":[178],"Albuminuria":[179],"at":[180],"104":[181],"weeks":[182],"15%":[190],"(95%":[191],"\u221241,":[193],"31)":[194],"users":[197],"33%":[199],"(26,":[200],"39)":[201],"non-users":[203],"(P-interaction=0.22).":[206],"decline":[208],"similarly":[210],"(P-interaction=0.71).":[214],"safety":[216],"profile":[217],"comparable":[221],"between":[222],"subgroups.":[223],"Conclusions:":[224],"participants":[226],"T2D":[228],"CKD,":[230],"consistent":[231],"benefits":[232],"outcomes,":[238],"MACE,":[239],"observed":[244],"regardless":[245]},"counts_by_year":[{"year":2026,"cited_by_count":1}],"updated_date":"2026-10-14T16:39:01.820549","created_date":"2025-10-10T00:00:00"}